Search

Brian Richardson

Dr Brian Richardson was a member of The Leadership Team and The Global Head of The Musculoskeletal Disease Therapeutic Area at The Novartis Institutes for Biomedical Research, having previously held several other senior positions during a 42-year career in the pharmaceutical industry. He was deputy head of drug safety, head of pathology and experimental toxicology, head of immunology, inflammation and respiratory research as well as Senior Project Manager for the worldwide development of new therapies for metabolic, cardiovascular and respiratory diseases for Sandoz Pharma. Dr Richardson was subsequently appointed head of preclinical research in Switzerland and UK, and played a key role in the merger of the Sandoz and Ciba Research organisations that ultimately resulted in the creation of The Novartis Institutes for Biomedical Research. Research conducted in Dr Richardson’s laboratories led to the discovery, development and introduction of several new therapies. He has published more than 60 original peer reviewed research papers and contributed many book chapters in the fields of pathophysiology, endocrinology and receptor pharmacology.
Bio last updated 01 May 2017

Access to our data for Brian Richardson is only available to paid subscribers with access.

The search engine is Western Australia's most accurate and comprehensive business listings and searchable database.

Brian Richardson is linked to 1 organisation which is included in 1 list - Public Companies - Industrial.

To see the data you will need to .

Total Shareholder Return as at 30/11/18

1 year TSR5 year TSR
544thDimerix-36%-16%
560thHazer Group-39%
805thTV2U International-75%-52%
828thCarnegie Clean Energy-83%-31%
741 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Revenue

165th↓Dimerix$825k
167th↑Hazer Group$759k
168th↓Grandbridge$703k
170th↓TV2U International$640k
171st↓Carnegie Clean Energy$10.6m
239 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer